Functional Imaging for Prostate Cancer: Therapeutic Implications is organized by Opus Medicus, Inc. and will be held from Jun 15, 2018 - Jun 15, 2021. This CME Conference has been approved for a maximum of 1.75 AMA PRA Category 1 Credit(s)™.

Course Description:
Functional radionuclide imaging modalities, now commonly combined with anatomical imaging modalities CT or MRI (SPECT/CT, PET/CT, and PET/MRI), are promising tools for the management of prostate cancer particularly for therapeutic implications. When used appropriately, the information from functional radionuclide imaging improves, and sometimes significantly changes, the whole course of the cancer management. In particular, while the localized prostate cancer is considered manageable, there is still significant need for improvement in noninvasive imaging of metastatic prostate cancer.

This course covers the rationale of using functional radionuclide imaging in prostate cancer management and the therapeutic implications for each prostate cancer radionuclide imaging agent.

Conference Objectives are:
• The rationale of using functional radionuclide imaging in prostate cancer management.
• Advantages of combining radionuclide and structural imaging modalities.
• Radionuclide imaging agents used for prostate cancer.
• Therapeutic implications for each of the radionuclide imaging agents

Additional details will be posted as soon as they are available.